Program
muvalaplin
Also written as “LY3473329”, “[14C]-LY3473329” and “Muvalaplin”.
Its studies are mostly in Atherosclerosis · Renal Insufficiency, led by Eli Lilly.
Furthest: phase 3, since Aug 28, 20256 company-led studies, 1 open or runningNext primary completion: Mar 2031 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 61 open or running | phase 3since Aug 28, 2025 | Jul 14, 2020 | Mar 2031phase 3 · NCT07157774 |
- Named in Eli Lilly’s own pipeline as
Muvalaplin
, phase 3, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 14, 2020First study: phase 1 study in HealthyFirst studyNCT04472676 · 86 enrolled · Netherlands
- Sep 7, 2021Phase 1 study in HealthyNCT05038787 · 24 enrolled · United States
- Sep 28, 2022Phase 2 study in AtherosclerosisNCT05563246 · 233 enrolled · United States, Australia, Brazil and more
- Mar 10, 2023Phase 1 study in Renal InsufficiencyNCT05778864 · 47 enrolled · United States
- Feb 26, 2024Phase 1 study in HealthyNCT06342596 · 16 enrolled · United Kingdom
- Aug 28, 2025Phase 3 study in AtherosclerosisNCT07157774 · 10,450 planned · United States, Argentina, Australia and more
Ahead
- Mar 2031Primary completion: phase 3 study in AtherosclerosisNCT07157774
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07157774Atherosclerosis · United States, Argentina, Australia and more | 3 | Recruiting | Mar 2031 | 10,450 |
| NCT06342596Healthy · United Kingdom | 1 | Completed | May 1, 2024 | 16 |
| NCT05778864Renal Insufficiency · United States | 1 | Completed | Sep 6, 2024 | 47 |
| NCT05563246Atherosclerosis · United States, Australia, Brazil and more | 2 | Completed | Mar 14, 2024 | 233 |
| NCT05038787Healthy · United States | 1 | Completed | Apr 7, 2022 | 24 |
| NCT04472676Healthy · Netherlands | 1 | Completed | Nov 9, 2021 | 86 |
How it is read
Names in the registry
- “LY3473329”, 5 entries
- “[14C]-LY3473329”, 2 entries
- “Muvalaplin”, 1 entry
Conditions, from the studies’ own filings
- Atherosclerosis, 2 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.